WARREN SCOTT PEAR
Medical Practice in Philadelphia, PA

2003018, Sep 25, 2003

Mar 10, 2003

10/385591

Warren Pear - Philadelphia PA, US
David Allman - Havertown PA, US
Yiping He - Philadelphia PA, US
David Izon - Wembley, AU
Jon Aster - Lexington MA, US

A61K038/17

514/012000

Provided are methods for manipulating aspects of lymphopoiesis by modulating and controlling Notch signaling, thereby providing treatment for diseases of the immune system. Accordingly, there are provided methods for selectively modulating T cell fate commitment of a common lymphoid progenitor at the expense of B cell fate commitment, and in the converse for selectively modulating B cell fate commitment of a common lymphoid progenitor at the expense of T cell fate commitment. Also provided are methods for treating patients suffering from a disease or disorder of T cell origin, or conversely of B cell origin. Further provided are methods for selectively killing B cells in a committed population of B cells, such as in a patient suffering from B cell leukemia or lymphoma; as well as methods for selectively killing T cells in a committed population of T cells such as in a patient suffering from diseases of T cell origin.

2011001, Jan 20, 2011

Jan 19, 2007

12/087949

Warren S. Pear - Philadelphia PA, US
Karen Keeshan - Philadephia PA, US
Yiping He - Phildephia PA, US

A61K 39/395, C12Q 1/68, G01N 33/68, C12N 5/078, A61K 38/02, A61K 31/7105, A61K 31/7088, A61P 35/02

4241731, 435 6, 435 724, 435375, 514 11, 514 44 A, 514 44 R, 514 196

Provided are methods for the diagnosis and treatment of acute myelogenous leukemia. In particular, the present invention relates to the use of Trib2 polynucleotides and polypeptides for the diagnosis and treatment of acute myelogenous leukemia (AML) by assessing myeloid cells of a patient, or malignancies associated with Trib2, C/EBPαp30 or C/EBPαp42, such as AML or lung cancer, by assessing hematopoietic stem cells of the patient.